Home / Resource Library / Randomized phase 3 ALCANZA study of brentuximab vedotin vs physicians choice in cutaneous T-cell lymphoma: final data

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physicians choice in cutaneous T-cell lymphoma: final data

Results of a phase III study investigating brentuximab vedotin for treatment of cutaneous t-cell lymphoma.